Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease Jul 18, 2022
Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease Jul 18, 2022
Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson’s Disease Jun 30, 2022
Cynapsus Therapeutics Announces Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders Jun 21, 2022
Cynapsus Therapeutics Announces Data Presentations at the European Academy of Neurology Annual Meeting May 30, 2022
Cynapsus Therapeutics Reports First Quarter 2016 Financial Results and Recent Developments May 11, 2022
